"Unilife will give access to its large-volume wearable injectors on a non-exclusive basis. This is a platform agreement, which means the drug-maker will be able to use these injectors for any of its products. We note that Amgen has an extensive product line that includes Repatha®, its PCSK9 inhibitor for hypercholesterolemia, that is now administered in three consecutive subcutaneous injections.
Amgen will have exclusive access to Unilife’s 1 mL wearable injector for certain small-volume drugs. The medicines have not been identified, but two biosimilars, adalimumab (Humira®) and infliximab (Remicade®), are under development that might gain a competitive advantage by being offered in Unilife’s device. Also, Amgen’s osteoporosis drug Prolia® requires a painful subcutaneous injection now and might benefit from a slower rate of administration achievable with a wearable injector." -- Keith Markey Jan 3 2016.
That somewhat summarizes the Jan 3 2016 announcement from the 8-K
